SG10202001404VA - Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers - Google Patents

Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers

Info

Publication number
SG10202001404VA
SG10202001404VA SG10202001404VA SG10202001404VA SG10202001404VA SG 10202001404V A SG10202001404V A SG 10202001404VA SG 10202001404V A SG10202001404V A SG 10202001404VA SG 10202001404V A SG10202001404V A SG 10202001404VA SG 10202001404V A SG10202001404V A SG 10202001404VA
Authority
SG
Singapore
Prior art keywords
peptides
cancers
combination
pancreatic cancer
immunotherapy against
Prior art date
Application number
SG10202001404VA
Other languages
English (en)
Inventor
Toni Weinschenk
Jens Fritsche
Harpreet Singh
Andrea Mahr
Martina Ott
Claudia Wagner
Oliver Schoor
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of SG10202001404VA publication Critical patent/SG10202001404VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001174—Proteoglycans, e.g. glypican, brevican or CSPG4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
SG10202001404VA 2015-03-17 2016-03-17 Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers SG10202001404VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562134253P 2015-03-17 2015-03-17
GB201504502A GB201504502D0 (en) 2015-03-17 2015-03-17 Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers

Publications (1)

Publication Number Publication Date
SG10202001404VA true SG10202001404VA (en) 2020-04-29

Family

ID=53016273

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202001404VA SG10202001404VA (en) 2015-03-17 2016-03-17 Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
SG11201706155XA SG11201706155XA (en) 2015-03-17 2016-03-17 Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201706155XA SG11201706155XA (en) 2015-03-17 2016-03-17 Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers

Country Status (19)

Country Link
US (2) US10076560B2 (fr)
EP (1) EP3270952A1 (fr)
JP (1) JP6715856B2 (fr)
KR (1) KR20170126929A (fr)
CN (2) CN107428810B (fr)
AR (2) AR121588A2 (fr)
AU (4) AU2016232140B2 (fr)
BR (1) BR112017019217A2 (fr)
CA (1) CA2979506A1 (fr)
CR (3) CR20210234A (fr)
EA (1) EA037783B1 (fr)
GB (1) GB201504502D0 (fr)
MA (3) MA40713A1 (fr)
MX (1) MX2017011857A (fr)
PE (1) PE20171515A1 (fr)
SG (2) SG10202001404VA (fr)
TW (2) TWI769586B (fr)
UA (1) UA123392C2 (fr)
WO (1) WO2016146751A1 (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160008399A1 (en) 2013-01-14 2016-01-14 Fred Hutchinson Cancer Research Center Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse
US10988543B2 (en) 2015-11-11 2021-04-27 Opi Vi—Ip Holdco Llc Humanized anti-tumor necrosis factor alpha receptor 2 (anti-TNFR2) antibodies and methods of use thereof to elicit an immune response against a tumor
AU2016369519B2 (en) 2015-12-16 2023-04-20 Gritstone Bio, Inc. Neoantigen identification, manufacture, and use
JP7075125B2 (ja) 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
GB201609193D0 (en) 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
EP4317432A3 (fr) 2016-12-08 2024-04-17 Immatics Biotechnologies GmbH Récepteurs de lymphocytes t à appariement amélioré
JP7295360B2 (ja) * 2016-12-21 2023-06-21 モナーク・バイオサイエンシズ・インコーポレイテッド 固形腫瘍細胞及びエスケープバリアントを治療するための足場
BR112019020959A2 (pt) * 2017-04-10 2020-05-05 Immatics Biotechnologies Gmbh peptídeos e combinações dos mesmos para uso na imunoterapia contra câncer
AU2018273958B2 (en) 2017-05-25 2022-07-21 Leidos, Inc. PD-1 and CTLA-4 dual inhibitor peptides
DE102017115966A1 (de) 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh Polypeptidmolekül mit verbesserter zweifacher Spezifität
AU2018298884A1 (en) 2017-07-14 2020-02-27 Immatics Biotechnologies Gmbh Improved dual specificity polypeptide molecule
AU2018348165A1 (en) 2017-10-10 2020-05-21 Gritstone Bio, Inc. Neoantigen identification using hotspots
CA3083097A1 (fr) 2017-11-22 2019-05-31 Gritstone Oncology, Inc. Reduction de la presentation d'epitope de jonction pour des neo-antigenes
DE102017127984B4 (de) 2017-11-27 2019-12-05 Immatics US, Inc. Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen
JP7470640B2 (ja) * 2018-02-09 2024-04-18 イマティクス ユーエス，アイエヌシー． Ｔ細胞を製造する方法
WO2019168524A1 (fr) 2018-02-27 2019-09-06 Leidos, Inc. Inhibiteurs peptidiques de pd-1
WO2019175380A2 (fr) * 2018-03-16 2019-09-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Peptides antigéniques dérivés de sécrétogranine v et leurs utilisations pour le diagnostic et le traitement du diabète de type 1
WO2019175384A2 (fr) * 2018-03-16 2019-09-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Peptides antigéniques dérivés de l'urocortine 3 et leurs utilisations pour le diagnostic et le traitement du diabète de type 1
US20200297768A1 (en) 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
JP2022533711A (ja) 2019-05-22 2022-07-25 レイドス， インコーポレイテッド Ｌａｇ３結合ペプチド
WO2020243134A1 (fr) 2019-05-27 2020-12-03 Immatics US, Inc. Vecteurs viraux et leur utilisation dans une thérapie cellulaire adoptive
US20200384028A1 (en) 2019-06-06 2020-12-10 Immatics Biotechnologies Gmbh Sorting with counter selection using sequence similar peptides
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
MX2022010461A (es) 2020-02-24 2022-12-13 Immatics Us Inc Metodos para expandir linfocitos t para el tratamiento de cancer y neoplasias malignas asociadas.
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
WO2021222621A1 (fr) * 2020-04-29 2021-11-04 Taipei Medical University Méthode de détection précoce, de prédiction de la réponse au traitement et de pronostic du cancer colorectal
WO2022026496A2 (fr) 2020-07-31 2022-02-03 Leidos, Inc. Peptides se liant à lag3
TW202227616A (zh) 2020-08-21 2022-07-16 美商英麥提克斯股份有限公司 分離ｃｄ８＋選擇ｔ細胞的方法
WO2022081426A1 (fr) 2020-10-12 2022-04-21 Leidos, Inc. Peptides immunomodulateurs
CN112557347B (zh) * 2020-11-12 2023-10-24 渤海大学 一种黏液层中乳糜粒子迁移模型的制备及检测方法
CN112462066B (zh) * 2020-12-03 2023-05-19 中南大学湘雅医院 Fam3c蛋白及其特异性抗体在制备检测鼻咽癌试剂盒中的应用、试剂盒及其应用
TW202241938A (zh) 2020-12-31 2022-11-01 美商英麥提克斯股份有限公司 Ｃｄ８多肽、組合物及其使用方法
CN112760383B (zh) * 2021-03-02 2023-07-21 上海欧易生物医学科技有限公司 应用于肺腺癌细胞亚群的一组qRT-PCR内参基因及其应用
AU2022269828A1 (en) 2021-05-05 2023-11-23 Immatics Biotechnologies Gmbh Bma031 antigen binding polypeptides
WO2023025851A1 (fr) 2021-08-24 2023-03-02 Immatics US, Inc. Sélection de cellules immunitaires à l'aide de complexes peptide-cmh générés par échange de ligands conditionnel
US20230089392A1 (en) 2021-09-20 2023-03-23 Immatics US, Inc. Monocyte depletion of t cells populations for t-cell therapy
WO2023081925A1 (fr) 2021-11-08 2023-05-11 Immatics Biotechnologies Gmbh Traitement combiné de thérapie cellulaire adoptive et compositions associées
KR102618065B1 (ko) * 2021-12-10 2023-12-22 성균관대학교산학협력단 췌장암 진단용 조성물 및 이를 이용한 췌장암 진단 방법
CN114214406A (zh) * 2021-12-15 2022-03-22 天津医科大学总医院 一种用于评价肿瘤患者免疫治疗反应性和评估肿瘤预后的三联标志物及其应用
US20230348548A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2023212691A1 (fr) 2022-04-28 2023-11-02 Immatics US, Inc. Polypeptides récepteurs de tgfβ négatifs dominants, polypeptides cd8, cellules, compositions et leurs méthodes d'utilisation
WO2023212655A1 (fr) 2022-04-28 2023-11-02 Immatics US, Inc. Polypeptides d'il-12, polypeptides d'il-15, polypeptides d'il-18, polypeptides de cd8, compositions et leurs procédés d'utilisation
US20230355678A1 (en) 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5610031A (en) * 1993-10-27 1997-03-11 The General Hospital Corporation B1k chain of laminin and methods of use
US6316213B1 (en) * 1997-03-19 2001-11-13 The Board Of Trustees Of The University Of Arkansas Methods for the early diagnosis of ovarian, breast and lung cancer
WO1999064627A2 (fr) * 1998-06-06 1999-12-16 Genostic Pharma Limited Sondes utilisees pour profilage genetique
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
CN1469926A (zh) * 2000-03-29 2004-01-21 科里克萨有限公司 治疗和诊断肺癌的组合物和方法
WO2003010327A2 (fr) * 2001-02-21 2003-02-06 Curagen Corporation Nouvelles proteines et acides nucleiques les codant
US20030021796A1 (en) * 2001-05-04 2003-01-30 Leszek Ignatowicz Method of enhancing T cell immunity by selection of antigen specific T cells
JP2003321494A (ja) * 2002-02-26 2003-11-11 Daiichi Fine Chemical Co Ltd プロｍｍｐ−７の活性化調節方法
EP2070949B1 (fr) * 2002-06-10 2013-01-16 Vaccinex, Inc. Anticorps anti-C35 et leur application pour le traitement du cancer
US20070224201A1 (en) * 2002-10-02 2007-09-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2003298014A1 (en) * 2002-12-04 2004-06-23 Diadexus, Inc. Compositions, splice variants and methods relating to colon specific genes and proteins
ATE440107T1 (de) * 2005-09-05 2009-09-15 Immatics Biotechnologies Gmbh Tumorassoziierte peptide, die hla klasse i oder ii-moleküle binden, und anti-tumor impfstoffe
GB0611116D0 (en) * 2006-06-06 2006-07-19 Oxford Genome Sciences Uk Ltd Proteins
UA103751C2 (ru) * 2007-07-27 2013-11-25 Имматикс Биотекнолоджис Гмбх Иммуногенный пептид для иммунотерапии
EP2127664A1 (fr) * 2008-02-15 2009-12-02 Max-Delbrück-Centrum Changement de l'état de charge de molécules MHC par des dipeptides
US20110117645A1 (en) * 2008-03-31 2011-05-19 Oriental Yeast Co., Ltd. Method for proliferation of pluripotent stem cells
DK2119726T5 (en) * 2008-05-14 2018-03-26 Immatics Biotechnologies Gmbh Novel and powerful MHC class II peptides derived from survivin and neurocan
US8568996B2 (en) * 2008-10-21 2013-10-29 University of Pittsburgh—of the Commonwealth System of Higher Education MMP activation peptide detection in biological samples
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
EP2550529B1 (fr) * 2010-03-23 2021-11-17 Iogenetics, LLC. Procédés bioinformatiques pour déterminer la liaison de peptides
AU2012203810B2 (en) * 2011-06-22 2013-12-05 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of bladder cancer
AU2012301664A1 (en) * 2011-08-31 2014-02-27 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of cancer
EP2771349B1 (fr) * 2011-09-16 2020-02-26 Iogenetics, LLC. Procédés bio-informatiques de détermination de liaisons peptidiques
US20140065620A1 (en) * 2011-12-29 2014-03-06 Mayo Foundation For Medical Education And Research Nucleic acids for detecting breast cancer
TWI777197B (zh) * 2013-08-05 2022-09-11 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（六）
CN104163862B (zh) * 2013-12-04 2017-02-08 魏敏杰 与人mhc‑i类分子结合的grp78多肽表位
CN104306976A (zh) * 2014-04-26 2015-01-28 深圳市康尔诺生物技术有限公司 一种高效的肿瘤个体化免疫治疗方法及其应用

Also Published As

Publication number Publication date
SG11201706155XA (en) 2017-09-28
US20180207251A1 (en) 2018-07-26
TWI726872B (zh) 2021-05-11
AU2020220070A1 (en) 2020-09-03
AR121588A2 (es) 2022-06-22
MA40713A1 (fr) 2018-11-30
AU2016232140A1 (en) 2017-09-07
EA201791853A1 (ru) 2017-12-29
AR121587A2 (es) 2022-06-22
US10357551B2 (en) 2019-07-23
CN107428810B (zh) 2022-08-19
AU2020220073A1 (en) 2020-09-03
UA123392C2 (uk) 2021-03-31
TW201643187A (zh) 2016-12-16
AU2020220073B2 (en) 2021-10-14
AU2020220072A1 (en) 2020-09-03
JP2018510628A (ja) 2018-04-19
JP6715856B2 (ja) 2020-07-01
CA2979506A1 (fr) 2016-09-22
MA46648A1 (fr) 2021-02-26
CN107428810A (zh) 2017-12-01
BR112017019217A2 (pt) 2018-04-10
MA46648B2 (fr) 2023-01-31
CN113563456A (zh) 2021-10-29
EP3270952A1 (fr) 2018-01-24
AU2020220072B2 (en) 2021-11-25
US10076560B2 (en) 2018-09-18
CR20210233A (es) 2021-06-25
MX2017011857A (es) 2018-04-24
US20170165335A1 (en) 2017-06-15
MA46647A1 (fr) 2021-10-29
TW202124427A (zh) 2021-07-01
AU2016232140B2 (en) 2020-07-02
AU2020220070B2 (en) 2021-12-02
GB201504502D0 (en) 2015-04-29
PE20171515A1 (es) 2017-10-20
KR20170126929A (ko) 2017-11-20
CR20210234A (es) 2021-06-25
WO2016146751A1 (fr) 2016-09-22
EA037783B1 (ru) 2021-05-20
CR20170419A (es) 2017-11-22
TWI769586B (zh) 2022-07-01

Similar Documents

Publication Publication Date Title
HRP20210709T8 (hr) Peptidi i kombinacija peptida za imunoterapiju protiv karcinoma prostate i druge vrste karcinoma
SG10202001404VA (en) Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
HK1252868A1 (zh) 用於卵巢癌和其他癌症免疫治療的新型肽和肽組合物
SG10202101368WA (en) Novel peptides and combination of peptides for use in immunotherapy against various cancers
SG10202001665QA (en) Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
IL258599A (en) New peptides and a combination of peptides used in immunotherapy against breast cancer and other types of cancer
GB201511792D0 (en) Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers
HUE054453T2 (hu) Új peptidek és peptidkombinációk az emlõrák és más ráktípusok elleni immunterápiában történõ használatra
HK1255542A1 (zh) 用於食管癌和其他癌症免疫治療的新型肽和肽組合物
IL256160A (en) New peptides and their combination for use in immunotherapy and methods for creating scaffolds for use against pancreatic cancer and other types of cancer
HK1255541A1 (zh) 用於多種癌症免疫治療的新型肽和肽組合物
IL280879A (en) Innovative peptides and a combination of peptides for use in immunotherapy against pancreatic cancer and other cancers